<DOC>
	<DOCNO>NCT00593645</DOCNO>
	<brief_summary>This study test combination clofarabine , cytarabine , thymoglobulin non-myeloablative conditioning regimen patient myelodysplastic syndrome acute myeloid leukemia undergo allogeneic stem cell transplant .</brief_summary>
	<brief_title>Clofarabine , Cytarabine , Thymoglobulin Allogeneic Transplantation</brief_title>
	<detailed_description>Current reduce intensity conditioning regimens able decrease TRM ( treatment relate mortality ) suffer increase rate disease relapse . Disease burden transplantation , measure percent myeloblast , predicts relapse . Current regimen employ fludarabine busulfan various adjutant , agent part usual armamentarium use versus leukemia questionable anti-leukemic activity . By substitute clofarabine cytarabine , combination proven anti-leukemic activity relapse refractory set well activity versus MDS , back bone regimen hope overcome residual disease improve post-transplant relapse rate . Furthermore principal toxicity regimen myelosuppression , abrogate infusion stem cell . Thymoglobulin include due minimal contribution toxicity significant benefit engraftment , control acute chronic GVHD , major contributor TRM disease specific activity MDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Inclusion Criteria ( Patient ) : 1 . Myelodysplastic Syndrome ( MDS ) , define World Health Organization criterion , OR Chronic Myelomonocytic Leukemia ( CMML ) define French American British classification OR Acute Myeloid Leukemia ( AML ) complete remission [ exclude FABM3 ] diagnose standard criterion meet criterion : 1 . Patients may CR 2 . No 2 cycle consolidation . Any consolidation regimen may use . 3 . No 6 month document CR transplant . 2 . Age 18 year old . 3 . ECOG performance status &lt; =2 4 . Identification suitable donor 5 . DLCO &gt; =40 % symptomatic pulmonary disease 6 . LVEF MUGA &gt; = 30 % 7 . Serum creatinine &lt; =1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 calculate Modification Diet Renal Disease equation Predicted GFR ( ml/min/1.73 m2 ) = 186 x ( Serum Creatinine ) 1.154 x ( age year ) 0.023 x ( 0.742 patient female ) x ( 1.212 patient black ) . 8 . Bilirubin &lt; =2 time upper limit normal 9 . AST &lt; =3 time upper limit normal Donor criterion : 1 . HLAMatched Sibling : The donor must adequate HLA match determine serologic type class ( A , B ) low resolution molecular type class II ( DRB1 ) define institutional standard . 2 . Matched Unrelated Donor : An acceptable match per NMDP standard base high resolution molecular typing . 3 . The donor must healthy must acceptable donor per institutional standard stem cell collection . 4 . The donor must significant cardiopulmonary , renal , endocrine , hepatic disease . 5 . There upper age restriction donor , must least 18 year age . 6 . Syngeneic donor eligible . 7 . No known HIV . 1 . Pregnant nursing . 2 . Active systemic infection consider opportunistic , life threaten clinically significant time treatment . 3 . Severe concurrent disease , include severe insulindependent diabetes , uncontrolled hypertension , transient ischemic attack , uncontrolled symptomatic coronary artery disease , symptomatic CNS involvement psychiatric illness/social situation would limit compliance study requirement . 4 . Known HIV disease . 5 . History malignancy except basal cell squamous cell carcinoma skin carcinoma situ cervix breast unless subject treatment free disease &gt; 3 year . 6 . Active disease time transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Conditioning regimen</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Nonmyeloablative conditioning</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Anti-thymocyte globulin</keyword>
</DOC>